MTP - Midatech's MTX110 shows survival benefit in rare pediatric brain cancer study shares up 37%

Midatech Pharma (MTP) rallies premarket after announcing positive results from a Phase I study evaluating MTX110, an investigational nano-inclusion product, for the treatment of the fatal childhood brain cancer in patients with diffuse intrinsic pontine glioma ((DPIG)).At interim data cutoff, median overall survival ((OS)) was 26.1 months. OS at month 12 was 71.4% (n=5/7).The primary endpoint of the planned 19-subject Phase 2 trial will be OS at month 12. MTX110 will be delivered using an alternative CED catheter system that enables regular drug infusions directly into the tumour without a need for repeated surgery.Shares up 37% premarket on robust volume.

For further details see:

Midatech's MTX110 shows survival benefit in rare pediatric brain cancer study, shares up 37%